William Stohl, MD, PhD

Professor of Medicine

Chief, Division of Rheumatology

Is this your profile? Click to edit

Overview

Dr. Stohl’s research focus is on systemic lupus erythematosus (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); rheumatoid arthritis (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); Sjogren’s syndrome (biomarkers, novel therapeutics); and B cells (basic biology, role in autoimmune diseases, development of targeted therapies).

Dr. Stohl received his M.D. (1977) and his Ph.D. (1979) from the University Pennsylvania.

Awards

University of Pennsylvania School of Medicine: Upjohn Award, 1979
Arthritis Foundation Southern California Chapter: James R. Klinenberg, M.D. Award, 2003

Research Funding

The vital role of BAFF in the development of SLE
NIH · R01AR050193 · May 16, 2006 – Aug 31, 2012 · Role: Principal Investigator
T CELL CYTOLYTIC ACTIVITY IN SLE
NIH · R01AR041006 · Aug 12, 1993 – Jun 30, 2002 · Role: Principal Investigator
POLYMORPHISM WITHIN T4/LEU3 AND SLE
NIH · R23AR036527 · Jan 1, 1986 – Jun 30, 1989 · Role: Principal Investigator

Media

Publications

Systemic lupus erythematosus: BAFF emerges from the genetic shadows. Nat Rev Rheumatol. 2017 08; 13(8):456-457.. View in PubMed
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Rheumatol. 2017 05; 69(5):1016-1027.. View in PubMed
A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens. J Clin Invest. 2017 May 01; 127(5):1651-1663.. View in PubMed
Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE). Expert Rev Clin Immunol. 2017 06; 13(6):623-633.. View in PubMed
Serum progranulin levels in Hispanic rheumatoid arthritis patients treated with TNF antagonists: a prospective, observational study. Clin Rheumatol. 2017 Mar; 36(3):507-516.. View in PubMed
B cell-independent contribution of BAFF to murine autoimmune disease. Clin Immunol. 2016 Nov; 172:111-116.. View in PubMed
Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors. Arthritis Rheumatol. 2015 Sep; 67(9):2523-35.. View in PubMed
Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015 Aug 20; 17:215.. View in PubMed
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Feb; 75(2):332-40.. View in PubMed
A dendritic-cell-stromal axis maintains immune responses in lymph nodes. Immunity. 2015 Apr 21; 42(4):719-30.. View in PubMed